PAC326: A Randomized, Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythermia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

This study will find out if an experimental drug called pacritinib works better than best available therapies.

Primary Sponsor:
CTI BioPharma Corp

Prinicipal Investigator:
Imad A.Tabbara, M.D.

Contact Phone:
(202) 741-2981

Are you interested in more information on this clinical trial?

First Name *
Last Name *
Email *
Street Address *
City *
State *
Zip Code *
Phone Number 
     
Verification Code *

Please type what you see (all uppercase):